These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 12270060)

  • 1. Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma.
    Jakob C; Zavrski I; Heider U; Brux B; Eucker J; Langelotz C; Sinha P; Possinger K; Sezer O
    Eur J Haematol; 2002 Jul; 69(1):37-42. PubMed ID: 12270060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios.
    Carlson K; Larsson A; Simonsson B; Turesson I; Westin J; Ljunghall S
    Eur J Haematol; 1999 May; 62(5):300-6. PubMed ID: 10359057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy.
    Abildgaard N; Brixen K; Kristensen JE; Eriksen EF; Nielsen JL; Heickendorff L
    Br J Haematol; 2003 Jan; 120(2):235-42. PubMed ID: 12542480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
    Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H
    J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen.
    Pecherstorfer M; Seibel MJ; Woitge HW; Horn E; Schuster J; Neuda J; Sagaster P; Köhn H; Bayer P; Thiébaud D; Ludwig H
    Blood; 1997 Nov; 90(9):3743-50. PubMed ID: 9345061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal bone turnover in monoclonal gammopathy of undetermined significance: analyses of type I collagen telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagens.
    Vejlgaard T; Abildgaard N; Jans H; Nielsen JL; Heickendorff L
    Eur J Haematol; 1997 Feb; 58(2):104-8. PubMed ID: 9111591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
    Ebert W; Muley T; Herb KP; Schmidt-Gayk H
    Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group (NMSG).
    Abildgaard N; Bentzen SM; Nielsen JL; Heickendorff L
    Br J Haematol; 1997 Jan; 96(1):103-10. PubMed ID: 9012695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma.
    Abildgaard N; Brixen K; Eriksen EF; Kristensen JE; Nielsen JL; Heickendorff L
    Haematologica; 2004 May; 89(5):567-77. PubMed ID: 15136220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myeloma.
    Samani KK; Brazier M; Mathiot C; Kamel S; Jamart J; Jaubert J; Blanc M; Azaïs I; Facon T; Leleu X
    Ann Hematol; 2005 Jan; 84(1):19-24. PubMed ID: 15338198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography.
    Jakob C; Zavrski I; Heider U; Bollow M; Schulz CO; Fleissner C; Eucker J; Michael R; Hamm B; Possinger K; Sezer O
    Clin Cancer Res; 2003 Aug; 9(8):3047-51. PubMed ID: 12912955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma.
    Abildgaard N; Glerup H; Rungby J; Bendix-Hansen K; Kassem M; Brixen K; Heickendorff L; Nielsen JL; Eriksen EF
    Eur J Haematol; 2000 Feb; 64(2):121-9. PubMed ID: 10997332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myeloma.
    Scudla V; Pika T; Budikova M; Petrova J; Minarik J; Bacovsky J; Langova K; Zivna J;
    Neoplasma; 2010; 57(2):102-10. PubMed ID: 20099972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis.
    Guañabens N; Parés A; Alvarez L; Martínez de Osaba MJ; Monegal A; Peris P; Ballesta AM; Rodés J
    J Bone Miner Res; 1998 Apr; 13(4):731-8. PubMed ID: 9580479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma.
    Jakob C; Sterz J; Liebisch P; Mieth M; Rademacher J; Goerke A; Heider U; Fleissner C; Kaiser M; von Metzler I; Müller C; Sezer O
    Leukemia; 2008 Sep; 22(9):1767-72. PubMed ID: 18580957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients.
    Alexandrakis MG; Passam FH; Malliaraki N; Katachanakis C; Kyriakou DS; Margioris AN
    Clin Chim Acta; 2002 Nov; 325(1-2):51-7. PubMed ID: 12367766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis.
    Al-Awadhi A; Olusi S; Al-Zaid N; Prabha K
    J Rheumatol; 1999 Jun; 26(6):1250-6. PubMed ID: 10381038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients.
    Fonseca R; Trendle MC; Leong T; Kyle RA; Oken MM; Kay NE; Van Ness B; Greipp PR
    Br J Haematol; 2000 Apr; 109(1):24-9. PubMed ID: 10848778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone resorption in healthy and osteoporotic postmenopausal women: comparison markers for serum carboxy-terminal telopeptide of type I collagen and urinary pyridinium cross-links.
    Välimäki MJ; Tähtelä R; Jones JD; Peterson JM; Riggs BL
    Eur J Endocrinol; 1994 Sep; 131(3):258-62. PubMed ID: 7921210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of bone mass in renal hyperparathyroidism by newly developed bone metabolic markers: evaluation of serum levels of carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen and carboxy-terminal propeptide of type I procollagen.
    Katagiri M; Fukunaga M; Ohtawa T; Harada T
    World J Surg; 1996 Sep; 20(7):753-6; discussion 756-7. PubMed ID: 8678946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.